Retatrutide : Phase 3 TRIUMPH-4 demonstrated 28.7% mean weight loss at 68 weeks with 12 mg dose (Phase 2 showed 24.2% at 48 weeks)
Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Sasai K, Iwabuchi K, Andreeff M , Konopleva M, Miida T
contact your prescriber for instructions on adjusted dosing or vial replacement
Eventually, Huntingtin aggregation interrupts the function of neurons, culminating into death of HD patients
Cagrilintides dose-dependent weight loss in both rodent models and human Phase 2 trials, combined with its dependence on AMYR/AMYR rather than CTR alone, supports a receptor-specific mechanism distinct from calcitonin-driven effects. The following comparison table summarizes cagrilintide alongside related peptides investigated in metabolic research models: Cagrilintide is studied for neuroendocrine signaling pathways, with particular focus on how amylin receptor activation in the central nervous system modulates appetite and energy balance
Advances in Glutathione Research for Disease Research Targeted therapy for GSH metabolism has become a research hotspot, and metabolomics and proteomics technologies have also provided powerful tools for GSH-related research: Targeting GSH metabolism : Inhibiting key molecules such as GCLC, xCT (cysteine uptake carrier) or SLC25A39 (mitochondrial GSH transporter), or using GSH-depleting nanozymes, has shown the potential to enhance ROS-mediated tumor cell death and improve related disease symptoms in preclinical models (such as cell models and animal models), providing new strategies for disease treatment
